公司资料
AtriCure 股价、新闻与催化剂
- 股票代码:
- ATRC
- 交易所:
- NASDAQ
- 行业:
- MedTech
- 所在地:
- United States
股票表现
44.77 USD (+1.06%)
收盘价
最后更新: 2026年8月17日
1.31B USD
市值
股价为何变动
As of Aug 17, 2026, ATRC closed up 1.06% at $44.77. No new same-company headline was identified in the current news window.
公司概览
Atrial Fibrillation Surgery
AtriCure develops medical devices and procedures for the surgical treatment of atrial fibrillation. Its products are used by cardiac surgeons to create controlled lesions that interrupt abnormal electrical pathways and restore a more regular heart rhythm.
Ablation Technologies
The Isolator Synergy Ablation System is FDA approved for persistent atrial fibrillation and anchors AtriCure’s surgical ablation portfolio. The company also offers the Hybrid AF Therapy, a minimally invasive approach for patients with long-standing persistent atrial fibrillation.
Adjacent Surgical Markets
AtriCure’s broader portfolio includes left atrial appendage management and post-operative pain-management products. These complementary technologies allow the company to serve multiple needs within cardiac and thoracic surgery using a common physician and hospital customer base.
未来催化剂
- AtriCure's catalysts are AF ablation adoption, left-atrial appendage management, and continued procedure growth in cardiac surgery. The company improves when its installed physician base keeps converting into repeatable use.
近期新闻
- 01
- 02
- 03
- 04
- 05
相似股票
商业成熟度、治疗领域或催化剂模式相近的同行公司。